And who might not
The blockbuster diabetes and weight loss drug semaglutide (Wegovy, Ozempic, Rybelsus) reduced the relative risk of heart attack, stroke, or cardiovascular deaths by 20 percent in high-risk patients with cardiovascular disease but not diabetes during a large and long randomized, placebo-controlled trial
The additional 5.4 cm greater waist reduction with tirzepatide is also clinically meaningful
This physiological effect contributes to increased satiety, reduced appetite, and improved postprandial glucose excursion
This transparent pricing model removes the financial uncertainty of dose-escalation ladders found with other providers
missing or taking doses late during tolerance trials creates cycles that lead to more hunger, frustration, and eventually giving up